151 related articles for article (PubMed ID: 31350344)
1. Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity.
Bartz R; Fukuchi K; Ohtsuka T; Lange T; Gruner K; Watanabe I; Hayashi S; Oda Y; Kawaida R; Komori H; Kashimoto Y; Wirtz P; Mayer JA; Redondo-Müller M; Saito S; Takahashi M; Hanzawa H; Imai E; Martinez A; Hanai M; Häussinger D; Chapman RW; Agatsuma T; Bange J; Abraham R
Mol Cancer Ther; 2019 Oct; 18(10):1832-1843. PubMed ID: 31350344
[TBL] [Abstract][Full Text] [Related]
2. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
Kanzaki H; Chiba T; Ao J; Koroki K; Kanayama K; Maruta S; Maeda T; Kusakabe Y; Kobayashi K; Kanogawa N; Kiyono S; Nakamura M; Kondo T; Saito T; Nakagawa R; Ogasawara S; Suzuki E; Ooka Y; Muroyama R; Nakamoto S; Yasui S; Tawada A; Arai M; Kanda T; Maruyama H; Mimura N; Kato J; Zen Y; Ohtsuka M; Iwama A; Kato N
Sci Rep; 2021 Mar; 11(1):5303. PubMed ID: 33674622
[TBL] [Abstract][Full Text] [Related]
3. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.
Desnoyers LR; Pai R; Ferrando RE; Hötzel K; Le T; Ross J; Carano R; D'Souza A; Qing J; Mohtashemi I; Ashkenazi A; French DM
Oncogene; 2008 Jan; 27(1):85-97. PubMed ID: 17599042
[TBL] [Abstract][Full Text] [Related]
4. Bile Acid Sequestration by Cholestyramine Mitigates FGFR4 Inhibition-Induced ALT Elevation.
Schadt HS; Wolf A; Mahl JA; Wuersch K; Couttet P; Schwald M; Fischer A; Lienard M; Emotte C; Teng CH; Skuba E; Richardson TA; Manenti L; Weiss A; Graus Porta D; Fairhurst RA; Kullak-Ublick GA; Chibout SD; Pognan F; Kluwe W; Kinyamu-Akunda J
Toxicol Sci; 2018 May; 163(1):265-278. PubMed ID: 29432567
[TBL] [Abstract][Full Text] [Related]
5. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models.
French DM; Lin BC; Wang M; Adams C; Shek T; Hötzel K; Bolon B; Ferrando R; Blackmore C; Schroeder K; Rodriguez LA; Hristopoulos M; Venook R; Ashkenazi A; Desnoyers LR
PLoS One; 2012; 7(5):e36713. PubMed ID: 22615798
[TBL] [Abstract][Full Text] [Related]
6. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
Gao L; Shay C; Lv F; Wang X; Teng Y
Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785
[TBL] [Abstract][Full Text] [Related]
7. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
Mellor HR
Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
[TBL] [Abstract][Full Text] [Related]
8. Making way for suppressing the FGF19/FGFR4 axis in cancer.
Prieto-Dominguez N; Shull AY; Teng Y
Future Med Chem; 2018 Oct; 10(20):2457-2470. PubMed ID: 30325210
[TBL] [Abstract][Full Text] [Related]
9. FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis.
Chen T; Liu H; Liu Z; Li K; Qin R; Wang Y; Liu J; Li Z; Gao Q; Pan C; Yang F; Zhao W; Zhang Z; Xu Y
Oncogene; 2021 Jul; 40(30):4941-4953. PubMed ID: 34163030
[TBL] [Abstract][Full Text] [Related]
10. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
11. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO
Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118
[TBL] [Abstract][Full Text] [Related]
13. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.
Lang L; Shull AY; Teng Y
Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies.
Lang L; Teng Y
Cells; 2019 Jan; 8(1):. PubMed ID: 30634399
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling.
Pai R; Dunlap D; Qing J; Mohtashemi I; Hotzel K; French DM
Cancer Res; 2008 Jul; 68(13):5086-95. PubMed ID: 18593907
[TBL] [Abstract][Full Text] [Related]
16. Bile acids decrease hepatic paraoxonase 1 expression and plasma high-density lipoprotein levels via FXR-mediated signaling of FGFR4.
Gutierrez A; Ratliff EP; Andres AM; Huang X; McKeehan WL; Davis RA
Arterioscler Thromb Vasc Biol; 2006 Feb; 26(2):301-6. PubMed ID: 16284190
[TBL] [Abstract][Full Text] [Related]
17. The ileal FGF15/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in mice.
Li Q; Zhao Q; Zhang C; Zhang P; Hu A; Zhang L; Schroder PM; Ma Y; Guo Z; Zhu X; He X
J Physiol Biochem; 2018 May; 74(2):247-260. PubMed ID: 29468415
[TBL] [Abstract][Full Text] [Related]
18. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways.
Wu AL; Coulter S; Liddle C; Wong A; Eastham-Anderson J; French DM; Peterson AS; Sonoda J
PLoS One; 2011 Mar; 6(3):e17868. PubMed ID: 21437243
[TBL] [Abstract][Full Text] [Related]
19. Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4.
Bumbaca D; Wong A; Drake E; Reyes AE; Lin BC; Stephan JP; Desnoyers L; Shen BQ; Dennis MS
MAbs; 2011; 3(4):376-86. PubMed ID: 21540647
[TBL] [Abstract][Full Text] [Related]
20. Salvianolic acid B blocks hepatic stellate cell activation via FGF19/FGFR4 signaling.
Tian S; Chen M; Wang B; Han Y; Shang H; Chen J
Ann Hepatol; 2021; 20():100259. PubMed ID: 32980439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
